Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Frequently asked questions
What sector does Replimune Group Inc (REPL) operate in?
Replimune Group Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Replimune Group Inc (REPL) current stock price?
As of the latest data, Replimune Group Inc stock price is $12.47, with a previous close of $11.46. Replimune Group Inc gained $1.01 in the last trading session, representing a 8.81% increase.
What is Replimune Group Inc (REPL) current market capitalization?
Replimune Group Inc market cap is approximately 1.17 billion.
What is Replimune Group Inc (REPL) Earnings Per Share (EPS)?
The trailing EPS is -$3.15, and the forward EPS is -$2.09.
What is Replimune Group Inc (REPL) EBITDA?
Replimune Group Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -66.02 million.
Does Replimune Group Inc (REPL) pay dividends?
No. Replimune Group Inc does not pay a dividend.
When is Replimune Group Inc (REPL) next earnings report?
Replimune Group Inc is expected to release its next earnings report on September 30, 2026.
What is Replimune Group Inc (REPL) beta (volatility) score?
Replimune Group Inc has a beta of 0.942, meaning its volatility is roughly in line with the market.
